Symbols

XPH

State Street SPDR S&P Pharmaceuticals ETF·NYSE

--(--)

Key Stats

Assets Under Management

311.88MUSD

Fund Flows (1Y)

88.71MUSD

Dividend Yield

0.81%

Discount/Premium to NAV

0.14%

Shares Outstanding

5.30M

Expense Ratio

0.35%

About State Street SPDR S&P Pharmaceuticals ETF

Issuer

State Street Global Advisors

Brand

SPDR

Home Page

https://www.ssga.com/us/en/intermediary/etfs/state-street-spdr-sp-pharmaceuticals-etf-xph

Inception Date

Jun 19, 2006

Structure

Open-Ended Fund

Index Tracked

S&P Pharmaceuticals Select Industry Index

Management Style

Passive

Dividend Treatment

Distributes

Distribution Tax Treatment

Qualified dividends

Income Tax Type

Capital Gains

Max ST Capital Gains Rate

39.60%

Max LT Capital Gains Rate

20.00%

Primary Advisor

SSgA Funds Management, Inc.

Distributor

State Street Corp. (Fund Distributor)

XPH offers equal-weighted exposure to a narrow selection of US pharmaceutical companies, stretching across all market caps. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. The fund also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. Overall, XPH is a solid way to capture a less concentrated version of the pharma market. The index is rebalanced quarterly.